Recently, the 2026 PDI Pharmaceutical R&D & Innovation Conference and the Ceremony for the Release of the Top 100 Pharmaceutical R&D Rankings were grandly held, with the industry rankings officially announced. Huayi Pharmaceuticals (Anhui) Co., Ltd. secured two core awards, earning widespread industry recognition once again for its solid full-industry-chain CDMO capabilities and mature chemical drug R&D innovation strength.

· 2026 Top 100 Chemical Drug R&D Strength

· 2026 Top 20 Pharmaceutical CDMO Enterprises for the eighth consecutive year

The dual honors are both an accolade and a driving force for moving forward. From our initial emergence to our sustained presence at the forefront of the rankings, this significant recognition not only reflects the industry's acknowledgment of Huayi Pharma's comprehensive strength but also serves as a strong affirmation of our unwavering commitment to quality and dedicated service.

Staying True to Our Service Mission, Co-creating a New Era in Pharmaceuticals

Honors belong to the past; the future is forged through hard work. Huayi Pharma will continue to uphold our corporate value of "For Better World", deepening our efforts in the formulation CDMO sector. We remain steadfast in our commitment to "To make high quality drugs at affordable cost!" with quality as our cornerstone and service as our bridge. We look forward to advancing hand in hand with global partners to create a brighter future for the pharmaceutical industry!

We extend our gratitude to every partner for your trust and support. Huayi Pharma will always live up to your expectations!